1107, 2025
Shooting Cancer Highlights – Focus periodico su approvazioni e disponibilità di nuove terapie oncologiche a bersaglio molecolare
EMA June 6 - Durvalumab – NSCLC EGFR/ALK. The European [...]
2506, 2025
Shooting Cancer – ASCO 2025 Highlights: precision oncology in motion
Several studies presented at the 2025 American Society of [...]
2306, 2025
Shooting Cancer – ASCO 2025 Highlights: precision oncology in motion
More than half the sessions at the 2025 American [...]
603, 2025
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA January 9 - Osimertinib - NSCLC EGFR. The European [...]
1001, 2025
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA December 30 - Lazertinib + amivantamab – NSCLC EGFR. [...]
1311, 2024
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA August 22 - Amivantamab – NSCLC EGFR. The [...]
3009, 2024
Shooting Cancer Highlights – Periodic focus on regulatory status of new targeted therapies in oncology
EMA June 17 - Capivasertib – BC PIK3CA/AKT1/PTEN. The European Commission (EC) has [...]
1107, 2024
Shooting Cancer Highlights – Periodic Focus on regulatory status of new targeted therapies in oncology
EMA May 28 - Selpercatinib – Solid Tumours RET. [...]